Webinar Date/Time: Wednesday, November 8th, 2023 at 11am EST | 8am PST | 4pm GMT | 5pm CET
Join our webinar on November 8th to learn how you can use Gen AI in your clinical trials to be ahead of the curve in this ever-changing landscape.
Register Free: https://www.appliedclinicaltrialsonline.com/act/ai-support
Event overview
With Generative AI going mainstream, we will explore the benefits of Gen AI, how this will impact your clinical trial execution, and the potential risks to be mindful of. The world of clinical trials is heavily driven by generation of data and various documents which lends itself to the use of Generative AI for assisting clinical trials processes.
Key questions that come to mind as we consider the use of Generative AI in clinical trials are-
First, all of this must be weighed against the potential inherent risks that come with Generative AI such as AI hallucinations, data privacy, IP protection and the perceived risks of displacing the human role in the process. What will the future bring, and what is the right way forward? Join us for this important discussion.
Three key take-aways
Speakers:
Rajneesh Patil
Vice President, Clinical OperationsIQVIA
Rajneesh serves Clinical Operations at IQVIA as Head of Digital Strategy and Analytics Innovation. He is a gold medalist in Dental Surgery from India with Foundations in Public health from Australia and Digital Strategy- Executive from Harvard Business School, USA
Virupaxkumar Bonageri
Associate Director, Clinical Operations
IQVIA
Virupaxkumar is a technologist, Innovator, and Digital Transformation Leader with 15+ years of experience in driving business growth and efficiency using AI, analytics and automation to clinical operations to deliver differentiated outcomes in patient safety, site engagement, compliance and monitoring. He has a Masters in Software Engineering from the Birla Institute of Technology and Science, Pilani.
Register Free: https://www.appliedclinicaltrialsonline.com/act/ai-support
Study Finds Many Randomized Clinical Trials Have Poorly Justified Exclusion Criteria
January 21st 2025Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include at least one poorly justified exclusion, most commonly affecting pregnant or lactating individuals.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.